Compare Procter & Gamble Co (PG) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Procter & Gamble (PG) trades at $149.15, showing minimal daily movement with a neutral technical stance. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.59 versus $1.56 expected, and robust profitability metrics like a 50.33% gross margin. Recent developments include a multi-year WNBA partnership and ongoing dividend payments of $1.09 per share, supporting its defensive appeal amid market volatility.

PG offers stability with a 53.85% analyst buy rating and $160.50 consensus target, but premium valuations (P/E 21.65) and modest growth outlook pose near-term risks. Supply chain efficiencies and brand strength underpin resilience, though inflation and competitive pressures require monitoring for sustained shareholder returns.

Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.

The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.